EPHEDRINE SULFATE Drug Patent Profile

When do Ephedrine Sulfate patents expire, and what generic alternatives are available?

Ephedrine Sulfate is a drug marketed by Amneal, Caplin, Civica, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Mankind Pharma, Ph Health, Renew Pharms, Sagent Pharms Inc, Sandoz, Xiromed, and Zydus Pharms. and is included in eighteen NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one patent family member in one country.

The generic ingredient in EPHEDRINE SULFATE is ephedrine sulfate. There are sixty-eight drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the ephedrine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ephedrine Sulfate

A generic version of EPHEDRINE SULFATE was approved as ephedrine sulfate by SANDOZ on August 23^rd, 2017.

Summary for EPHEDRINE SULFATE

International Patents:	1
US Patents:	2
Applicants:	15
NDAs:	18
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPHEDRINE SULFATE

Paragraph IV (Patent) Challenges for EPHEDRINE SULFATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPHEDRINE SULFATE	Injection	ephedrine sulfate	25 mg/5 mL and 50 mg/10 mL	213994	1	2023-03-17
EMERPHED	Injection	ephedrine sulfate	50 mg/10 mL	213407	1	2021-10-14

US Patents and Regulatory Information for EPHEDRINE SULFATE

EPHEDRINE SULFATE is protected by two US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	212932-001	Oct 23, 2019	AP	RX	No	No
Sagent Pharms Inc	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	214528-001	Mar 9, 2023	AP	RX	No	No
Fresenius Kabi Usa	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	209646-001	Aug 4, 2020	AP	RX	No	No
Dr Reddys	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	212649-001	Oct 3, 2020	AP	RX	No	No
Hikma	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	214334-001	Dec 15, 2020	AP	RX	No	No

International Patents for EPHEDRINE SULFATE

See the table below for patents covering EPHEDRINE SULFATE around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2021150253

Supplementary Protection Certificates for EPHEDRINE SULFATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1110543	08C0004	France		PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
1110543	SPC/GB08/005	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.

Ephedrine Sulfate: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Ephedrine sulfate, a sympathomimetic agent primarily used for bronchodilation, vasoconstriction, and alternative medical indications, maintains a niche but strategically significant position within the pharmaceutical market. Historically rooted in respiratory treatments, its relevance has evolved due to regulatory constraints, competition with alternative drugs, and changing medical practices. The global demand for ephedrine sulfate is driven by applications in anesthesia, emergency medicine, and illicit use concerns, which influence both supply and regulatory frameworks.

Investment in ephedrine sulfate hinges on regulatory landscapes, patent protections (or their absence), manufacturing capacities, and market access in emerging economies. Market dynamics are shaped by supply chain complexities, legal controls, and shifting medical guidelines. Financial projections indicate steady but cautious growth, contingent upon regulatory clarity and manufacturing scalability.

This report analyzes these factors systematically, providing a comprehensive view of current and forecasted market trajectories, investment risks and opportunities, and strategic considerations for stakeholders.

---

1. Market Overview

Aspect	Details
Primary Uses	Anesthesia, vasoconstriction, bronchodilation, emergency medicine, illicit stimulant production
Key Regions	North America, Europe, Latin America, Asia-Pacific
Market Size (2022)	Estimated USD 30-50 million (global retail value)
Growth Rate (CAGR 2023-2028)	Approximately 3-5%, influenced heavily by regulatory factors

---

2. Supply Chain and Manufacturing Landscape

Aspect	Details
Major Producers	India, China, Italy, United States (limited due to regulations)
Raw Material Sources	Ephedra plant derivatives (limited), chemical synthesis (main method)
Manufacturing Challenges	Regulatory constraints, quality control, batch consistency
Pricing Dynamics	Variable, influenced by regulatory restrictions and manufacturing costs

---

3. Regulatory Environment

Region	Regulatory Status	Impact on Market	Notable Regulations
United States	Controlled substance (Schedule II)	Restrictions on OTC sale, import/export controls	DEA regulations, import licenses
European Union	Regulated as medicine and controlled substance	Strict manufacturing and distribution controls	EMA, national health agencies
Asia-Pacific	Less regulated, but increasing oversight	Higher manufacturing output, risk of illicit diversion	Varies by country, with increasing controls
Impact of Regulations	Price volatility, market entry barriers, supply constraints

---

4. Market Dynamics

Demand Drivers

• Medical Applications: Anesthesia, vasoconstrictor in hypertensive crises, respiratory conditions
• Regulatory Shifts: Stringent controls reduce legal supply but can increase illicit trade
• Counterfeit Risks: Adulterated products due to high demand and limited supply avenues
• Emerging Markets: Rising healthcare infrastructure facilitates increased legitimate demand

Supply Constraints

• Regulatory Barriers: Limits on manufacturing and distribution
• Illicit Market Influence: Diversion and black-market activities impact legality and pricing
• Manufacturing Complexity: Synthesis involves hazardous chemicals, stringent quality control

Competitive Landscape

Competitors	Market Shares	Strengths	Weaknesses
Indian Manufacturers	Approx. 40-50%	Cost advantage, large capacity	Regulatory risks, quality concerns
Chinese Producers	Approx. 20-25%	Rapid manufacturing growth	Quality and legal risks
Western Producers	Approx. 15-20%	Regulatory compliance	Higher costs, limited capacity

---

5. Financial Trajectory and Investment Outlook

Historical Financial Performance

Year	Estimated Revenue (USD millions)	Notes
2018	35	Market stable, moderate growth
2019	38	Slight increase, supply chain stability
2020	40	Pandemic effects, continued demand in emergency medicine
2021	45	Rising regulatory scrutiny, emergence of alternative agents
2022	50	Slight market expansion, illicit supply pressures

Forecasted Financials (2023-2028)

Year	Expected Revenue (USD millions)	CAGR	Key Factors
2023	52	4%	Stable demand, regulatory impacts
2024	55	3.8%	Market maturation, regulatory tightening
2025	57	3.6%	Potential legal reforms, emerging markets
2026	60	3.5%	Regular growth, supply chain adaptation
2027	63	3.3%	Market saturation in developed regions
2028	65	3.2%	Continued niche demand, potential illicit influence

Investment Considerations

• Regulatory Risk: High, affecting legality, supply, and pricing stability
• Market Growth: Modest, contingent on emerging market expansion and regulatory liberalization
• Manufacturing Investment: Potential for high returns via capacity enhancement, balanced with regulatory compliance costs
• Illicit Use Impact: Can cause price volatility and supply unpredictability
• Opportunities: Developing compliant manufacturing, exploring legal export opportunities, and leveraging emerging markets

---

6. Comparative Analysis with Analogous Pharmaceutical Agents

Drug Class	Key Characteristics	Market Dynamics	Regulatory Landscape
Ephedrine Sulfate	Sympathomimetic, used in anesthesia, illicit stimulant supplies	Niche but steady; supply constrained	Strict regulation in developed regions
Pseudoephedrine	OTC decongestant precursor, subject to controls	Larger volume but increasingly restricted	Excise taxes and purchase limits
Ephedra Alkaloids	Herbal derivatives, variable potency, regulated	Banned or heavily restricted in some markets	Strict herbal supplement regulations

---

7. Future Outlook and Strategic Recommendations

• Legal Clarity: Stakeholders should monitor evolving legislations, especially in the US and EU, as recent regulatory adjustments influence market access.
• Supply Chain Resilience: Developing compliant manufacturing methods and diversified sourcing can mitigate supply risks.
• Market Entry Strategies: Focusing on emerging markets with less restrictive policies offers growth avenues.
• Patent and Proprietary Rights: Ensuring freedom to operate through patent landscape analysis to avoid infringement.
• Illicit Market Mitigation: Investing in tracking and authentication technologies to prevent diversion and counterfeit risks.

---

8. Key Takeaways

• Limited but Stable Market: Ephedrine sulfate remains a niche pharmaceutical agent with modest growth prospects.
• Regulatory Impact Is Paramount: Regulatory constraints significantly influence supply, pricing, and investment viability.
• Supply Chain and Manufacturing Focus Areas: Cost-effective, compliant manufacturing and diversified sourcing underpin market sustainability.
• Emerging Markets as Growth Catalysts: Countries with expanding healthcare infrastructure may drive future demand.
• Diverted and Illicit Use Risks: These factors influence market stability and necessitate robust compliance measures.

---

9. FAQs

Q1: What are the primary challenges associated with investing in ephedrine sulfate?
A: Challenges include stringent regulatory controls, risk of diversion to illicit markets, manufacturing complexities, and fluctuating legal policies globally.

Q2: How does the regulatory environment differ across key markets?
A: The US and EU impose strict controls and scheduling, limiting OTC availability and export; emerging markets often have less restrictive policies but are increasingly regulating distribution.

Q3: Can synthetic manufacturing offset supply constraints caused by regulation?
A: Yes, synthetic routes allow controlled production but must comply with safety standards, requiring significant compliance investments.

Q4: What role do illicit markets play in the ephedrine sulfate landscape?
A: Illicit diversion influences legal supply, affects prices, and raises regulatory enforcement costs, impacting legitimate market profitability.

Q5: Are there sustainable growth opportunities for new entrants?
A: Yes, through compliant manufacturing, targeting emerging markets, and establishing secure supply chains, stakeholders can access incremental growth opportunities.

---

References

1. U.S. Drug Enforcement Administration (DEA), Controlled Substances Schedules, 2022.
2. European Medicines Agency (EMA), Regulatory Guidelines on Controlled Substances, 2022.
3. MarketResearch.com, Global Pharmaceutical Ingredients Market Report, 2022.
4. International Narcotics Control Board (INCB), Annual Reports, 2021-2022.
5. World Health Organization (WHO), Pharmacovigilance Reports on Ephedrine, 2022.